Clearmind Medicine Inc. (NASDAQ: CMND ) shares are sliding on Wednesday morning. The stock is undergoing a price correction following a massive two-day rally.
On Monday, the ticker skyrocketed over 100%, hitting highs near $1.52.
Clinical Trial Success Fuels Volatility
The initial surge followed positive Phase I/IIa clinical trial results for CMND-100 . The drug candidate targets Alcohol Use Disorder (AUD).
Clearmind reported the treatment met primary safety and tolerability endpoints.
The third cohort showed a strong safety profile. No serious adverse events occurred, even at the highest tested doses.
Regulatory Tailwinds
The company commended President Donald Trump's Saturday executive order.
The order directs the U.S. Food and Drug Administration (FDA) to prioritize breakthrough psychedelic therapies .
Technical Analysis
Clearmind's chart remains pinned near the low end of its 52-week range of $52.40 to 59 cents. The stock is trading 23.9% below its 20-day simple moving average (SMA) and 62.8% below its 100-day SMA.
Key Resistance: $1.00 — a round-number area near the 20-day SMA where rebounds can stall Key Support: 50 cents — a nearby "line in the sand" area around the recent 52-week low zoneCMND Stock Price Activity: Clearmind Medicine shares were down 9.68% at $0.74 during premarket trading on Wednesday, according to Benzinga Pro data .
Photo: boscorelli / Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Equities News Top Stories Markets Movers benzai why it's moving